Literature DB >> 11355743

Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas.

M Glaeser1, T Floetotto, B Hanstein, M W Beckmann, D Niederacher.   

Abstract

Steroid receptor coactivator 3 (SRC3) functions as a coactivator for nuclear receptor mediated transcriptional activation. It binds to nuclear receptors in a ligand-dependent fashion and recruits other factors such as CBP and p300 to the transactivation complex. Due to its function as activator of nuclear receptors, overexpression of SRC3 might enhance their effects. Gene amplification is a common mechanism that causes overexpression, already described for oncogenes like c-erbB2, c-myc and int2. In this study, SRC3 gene amplification and expression levels were analyzed in 127 sporadic breast carcinomas, 30 endometrial carcinomas and different cell lines (MCF7, HeLa, Ishikawa, T47D, BT-20, SK-BR-3, HEC-1a, RL 95-2, OVCAR3 and A-431). To determine gene amplification and mRNA expression levels, quantitative differential PCR and RT-PCR were performed in combination with fluorescent DNA technology. Gene amplification was not found in any of the breast and endometrial carcinomas, but was found in the carcinoma cell lines MCF7 (10-fold) and HeLa (3-fold). SRC3 overexpression was detected in 13% (3/23) of breast carcinomas and 17% (5/30) of endometrial carcinomas, as well as in MCF7 and HeLa cells. Thus, SRC3 overexpression found in breast and endometrial tumors is not caused by SRC3 gene amplification. A carcinogenic potential provided by SRC3 overexpression has to be elucidated in further studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355743     DOI: 10.1055/s-2001-14938

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  27 in total

1.  Limited tissue fixation times and whole genomic amplification do not impact array CGH profiles.

Authors:  A A Ghazani; N C R Arneson; K Warren; S J Done
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

Review 2.  Minireview: nuclear receptor coregulators of the p160 family: insights into inflammation and metabolism.

Authors:  David A Rollins; Maddalena Coppo; Inez Rogatsky
Journal:  Mol Endocrinol       Date:  2015-02-03

Review 3.  Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.

Authors:  Malachi A Blundon; Subhamoy Dasgupta
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

4.  The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation.

Authors:  Hina Naeem; Donghang Cheng; Qingshi Zhao; Caroline Underhill; Marc Tini; Marc T Bedford; Joseph Torchia
Journal:  Mol Cell Biol       Date:  2006-10-16       Impact factor: 4.272

5.  SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.

Authors:  Xianzhou Song; Hui Chen; Chengwei Zhang; Yang Yu; Zhongyuan Chen; Han Liang; George Van Buren; Amy L McElhany; William E Fisher; David M Lonard; Bert W O'Malley; Jin Wang
Journal:  Cancer Lett       Date:  2018-11-10       Impact factor: 8.679

6.  Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.

Authors:  Arthur C-K Chung; Suoling Zhou; Lan Liao; Jean Ching-Yi Tien; Norman M Greenberg; Jianming Xu
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

7.  The role of AIB1 in breast cancer.

Authors:  Alan K Chang; Huijian Wu
Journal:  Oncol Lett       Date:  2012-07-16       Impact factor: 2.967

8.  Role of the steroid receptor coactivator SRC-3 in cell growth.

Authors:  Ge Zhou; Yoshihiro Hashimoto; Inseok Kwak; Sophia Y Tsai; Ming-Jer Tsai
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 9.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.

Authors:  Jianming Xu; Ray-Chang Wu; Bert W O'Malley
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

10.  Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer.

Authors:  David M Lonard; Bert W O'Malley
Journal:  Clin Cancer Res       Date:  2016-09-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.